Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
Metrics: PDF 2237 views | HTML 1998 views | ?
Elin S. Gray1, Helen Rizos2,8, Anna L. Reid1, Suzanah C. Boyd2,8, Michelle R. Pereira1, Johnny Lo3, Varsha Tembe4, James Freeman1, Jenny H.J. Lee4,5, Richard A. Scolyer6,8, Kelvin Siew9, Chris Lomma9, Adam Cooper5, Muhammad A. Khattak10,11, Tarek M. Meniawy9,11, Georgina V. Long7,8, Matteo S. Carlino5,8, Michael Millward9,11 and Melanie Ziman1,12
1 School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
2 Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia
3 School of Engineering, Edith Cowan University, Joondalup, Western Australia, Australia
4 Centre for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia
5 Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia
6 Disciplines of Pathology, The University of Sydney, Sydney, New South Wales, Australia
7 Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
8 Melanoma Institute Australia, Sydney, New South Wales, Australia
9 Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
10 Department of Medical Oncology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
11 School of Medicine and Pharmacology, The University of Western Australia, Crawley, Western Australia, Australia
12 School of Pathology and Laboratory Medicine, The University of Western Australia, Crawley, Western Australia, Australia
Elin Gray, email:
Keywords: melanoma, ctDNA, acquired resistance, MAPK inhibition, immunotherapy
Received: August 03, 2015 Accepted: August 31, 2015 Published: September 22, 2015
Repeat tumor biopsies to study genomic changes during therapy are difficult, invasive and data are confounded by tumoral heterogeneity. The analysis of circulating tumor DNA (ctDNA) can provide a non-invasive approach to assess prognosis and the genetic evolution of tumors in response to therapy. Mutation-specific droplet digital PCR was used to measure plasma concentrations of oncogenic BRAF and NRAS variants in 48 patients with advanced metastatic melanoma prior to treatment with targeted therapies (vemurafenib, dabrafenib or dabrafenib/trametinib combination) or immunotherapies (ipilimumab, nivolumab or pembrolizumab). Baseline ctDNA levels were evaluated relative to treatment response and progression-free survival (PFS). Tumor-associated ctDNA was detected in the plasma of 35/48 (73%) patients prior to treatment and lower ctDNA levels at this time point were significantly associated with response to treatment and prolonged PFS, irrespective of therapy type. Levels of ctDNA decreased significantly in patients treated with MAPK inhibitors (p < 0.001) in accordance with response to therapy, but this was not apparent in patients receiving immunotherapies. We show that circulating NRAS mutations, known to confer resistance to BRAF inhibitors, were detected in 3 of 7 (43%) patients progressing on kinase inhibitor therapy. Significantly, ctDNA rebound and circulating mutant NRAS preceded radiological detection of progressive disease. Our data demonstrate that ctDNA is a useful biomarker of response to kinase inhibitor therapy and can be used to monitor tumor evolution and detect the early appearance of resistance effectors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.